After the close of trading on March 8, Zhejiang Ausun Pharmaceutical Co.Ltd(603229) ( Zhejiang Ausun Pharmaceutical Co.Ltd(603229) . SH) announced that the company planned to issue shares by non-public offering to specific objects. The funds raised in this offering would not exceed 500 million yuan, and the number of shares issued would not exceed about 28.7 million. The net amount after deducting the issuance expenses would be used for the internationalization project of high-end preparations (phase I) Industrialization project of characteristic APIs and key pharmaceutical intermediates (phase II), and supplement working capital.
Among them, 290 million yuan will be invested in the internationalization project of high-end preparations (phase I), 130 million yuan will be invested in the industrialization project of characteristic APIs and key pharmaceutical intermediates (phase II), and the remaining 80 million yuan will be used to supplement working capitalp align=”center” style=”text-align:center;”> Raised investment projects. Source: screenshot of announcement
Zhejiang Ausun Pharmaceutical Co.Ltd(603229) ‘s main business is the R & D, production and sales of characteristic APIs and pharmaceutical intermediates, as well as providing customized processing and R & D business for customers. At present, the company’s products are mainly divided into liver disease, respiratory system, cardio cerebrovascular, high-end fluorine products, prostaglandin, antibacterial, gout and antitumor.
The plan shows that through the implementation of the investment project with raised funds, Zhejiang Ausun Pharmaceutical Co.Ltd(603229) complies with the development trend of the industry and promotes the development strategy of upgrading the integrated industrial chain of intermediates + characteristic APIs + preparations; The company can also deepen its main business and further improve its profitability while solving the problem of tight production capacity; After the funds raised this time are in place, the company’s capital structure will be optimized and its capital strength will be enhanced, which will help to continuously increase R & D investment in the future.
Specifically, the construction period of high-end preparation internationalization project (phase I) is 2 years, and the implementation subject is Zhejiang Qizheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhejiang Ausun Pharmaceutical Co.Ltd(603229) with the construction site in Taizhou Zhejiang Ausun Pharmaceutical Co.Ltd(603229) disclosed in the announcement that the project is the phase I project of “Zhejiang Qizheng Pharmaceutical Co., Ltd. with an annual output of 450 million anti-tumor tablets and capsules and 3.9 billion solid tablets and capsules in Taizhou Bay circular economy industrial cluster”. At present, the project has completed the procedures of project filing and environmental assessment.
The industrialization project of characteristic API and key pharmaceutical intermediates (phase II) is planned to be constructed for 2 years. The main body of implementation is Zhejiang Ausun Pharmaceutical Co.Ltd(603229) , and the construction site is located in Taizhou Zhejiang Ausun Pharmaceutical Co.Ltd(603229) said that the above-mentioned phase II project is designed in terms of construction, equipment and process in full accordance with the cGMP drug production specifications of the United States, Europe and Japan and the strict EHS system. The raised investment project will be implemented on the existing plot of the company, located on the west side of the plant, and the relevant procedures such as filing and environmental assessment are being actively handled.
In addition, Zhejiang Ausun Pharmaceutical Co.Ltd(603229) plans to use 80 million yuan of the raised funds to supplement the working capital, so as to meet the working capital demand brought by the continuous growth of business scale in the future and further improve the overall profitability of the company.
Zhejiang Ausun Pharmaceutical Co.Ltd(603229) also pointed out the risk in the announcement that the raised investment project of high-end preparation internationalization project (phase I) is still in the construction period, the raised investment products are still in research and development, and have not obtained all the qualifications required for daily operation and product marketing. The qualifications required for the production and marketing of generic drugs mainly include drug production license and drug registration certificate. The company is actively promoting the fund-raising projects to obtain all required qualification licenses and drug registration approvals as soon as possible, and there are no major obstacles to obtaining them. If there is a major change in the national pharmaceutical management policy in the future, or the company’s personnel, production and technology do not meet the relevant requirements, the company still faces the risk of being unable to obtain all the qualification licenses or drug registration approvals required for the raised investment project; Meanwhile, the qualification acquisition time of the raised investment project is based on the judgment and calculation of the current construction and R & D progress, planning and industrial policies. If the construction and R & D Progress of the raised investment project is less than expected or the industrial policies change significantly, it will face the risk that the qualification acquisition time of the raised investment project is less than expected, which will have an adverse impact on the implementation progress of the raised investment project.
